WO2026126059 - HETEROCYCLIC COMPOUND
National phase entry is expected:
Publication Number
WO/2026/126059
Publication Date
18.06.2026
International Application No.
PCT/IB2025/062563
International Filing Date
08.12.2025
Title **
[English]
HETEROCYCLIC COMPOUND
[French]
COMPOSÉ HÉTÉROCYCLIQUE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
MIKAMI, Satoshi
KIKUCHI, Fumiaki
TOITA, Akinori
TANAKA, Yuta
YAMAGUCHI, Fumie
IMAMURA, Keisuke
HASUI, Tomoaki
YOSHIKAWA, Masato
KAMEI, Taku
TOYOFUKU, Masashi
WANG, Chunxiang
KAKEI, Hiroyuki
SUGIMOTO, Takahiro
HIDAKA, Kosuke
MORIMOTO, Shinji
NAKAMURA, Minoru
HOMMA, Misaki
KAMATA, Makoto
OGURO, Yuya
NAKAMURA, Shinji
IBANEZ SANCHEZ, Ignacio
Priority Data
63/729,723
09.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3509 | |
| EPO | Filing, Examination, Granting | 22582 | |
| Japan | Filing, Examination, Granting | 2833 | |
| South Korea | Filing, Examination, Granting | 3445 | |
| USA | Filing, Examination, Granting | 18190 |
Total:
50,559
Contact Us
Abstract[English]
are as defined in the specification, for treatment of a disease, disorder or condition associated with NLRP3, including a disease, disorder or condition associated with a heterozygous gain of function mutation in the NLRP3 gene such as cryopyrin-associated periodic syndrome (CAPS).[French]
étant tels que définis dans la description, pour le traitement d'une maladie, d'un trouble ou d'un état associé à NLRP3, y compris une maladie, un trouble ou un état associé à une mutation hétérozygote avec gain de fonction dans le gène NLRP3, telle que le syndrome périodique associé à la cryopyrine (CAPS).